FN2 Earnings Intelligence

Alnylam Pharmaceuticals, Inc. earnings overview

Latest Alnylam Pharmaceuticals, Inc. (ALNY) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.

Next reportAlnylam Pharmaceuticals, Inc. reports Thursday, Feb 18, 2027 · Before market openConsensus EPS $2.05 · consensus revenue $1.57B
ALNY FY2026 Q3 · Calendar Q4 2026

Alnylam Pharmaceuticals, Inc.

Alnylam's Q3 supports a growth case centered on continued AMVUTTRA uptake and pipeline progress, but demand conversion and reimbursement policy remain important execution risks.

EPS surprise+879.5%
Market move-25.1%

Get the ALNY recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.